title: [A Case of Pneumatosis Cystoides Intestinalis Secondary to Gefitinib Therapy for Lung Adenocarcinoma].
abstract: Pneumatosis cystoides intestinalis (PCI) is a relatively rare condition, characterized by subserosal or submucosal air within the bowel wall. Herein, we report a rare case of PCI secondary to treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). A 71-year-old man, who had received gefitinib therapy for 2 years and 5 months for lung adenocarcinoma with metastases to the bones and brain, presented with abdominal pain, diarrhea, and vomiting. Computed tomography of the abdomen revealed intramural air in the small bowel, free air in the abdomen, and moderate ascites. A diagnosis of PCI was made, and the patient was managed conservatively by discontinuing gefitinib treatment, because his vital signs were stable and there was no sign of peritonitis. The patient's symptoms gradually improved, and follow-up CT after 1 week revealed that the initial findings had almost completely resolved. Clinicians should note that treatment with gefitinib might cause PCI.
authors.affiliation: Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences.
authors.forename: Takuya
authors.initials: T
authors.lastname: Ando
authors.forename: Jun
authors.initials: J
authors.lastname: Sakata
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Maruyama
authors.forename: Yuki
authors.initials: Y
authors.lastname: Hirose
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Okabe
authors.forename: Kazuyasu
authors.initials: K
authors.lastname: Takizawa
authors.forename: Masayuki
authors.initials: M
authors.lastname: Nagahashi
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Shimada
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kameyama
authors.forename: Takashi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Minagawa
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kosugi
authors.forename: Yu
authors.initials: Y
authors.lastname: Koyama
authors.forename: Aya
authors.initials: A
authors.lastname: Ohtsubo
authors.forename: Satoshi
authors.initials: S
authors.lastname: Watanabe
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Wakai
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003967:Diarrhea / Q000209:etiology; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D011006:Pneumatosis Cystoides Intestinalis / Q000139:chemically induced* / Q000000981:diagnostic imaging; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D014839:Vomiting / Q000209:etiology
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib